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I. INTRODUCTION
Since the development of the radioimmunoassay for a soluble protein (insulin) by Yalow
and Berson in 1959,1,2 the immunoassay field has continuously progressed to more sensitive
and reproducible assays. This progress made it possible to trace compounds which are
relevant for all kinds of biological processes, e.g. , diseases, pregnancy, and poisoning. One
of the possibilities to improve these immunoassays further and to open new clinical research
areas is the application of a new type of label. Such a new label must have a unique set of
characteristics, such that it is preferable over existing labels used in immunoassay.
In 1981, we prepared a new type of label, a functionalized stable 1,2-dioxetane.3 Later,
we reported the first results of immunoassays in which stable 1,2-dioxetanes were used as so
called thermochemiluminescent (TCL) labels.4,5 In the present chapter, the development and
optimization of two types of solid-phase sandwich TCL immunoassays (TIA and FTIA) for
human chorionic gonadotropin (hCG) using the same type of 1,2-dioxetane label are
described. The results are compared to an existing sensitive hCG enzyme immunoassay, in
which the same set of antibodies is used.
Although well over 200 1,2-dioxetanes have been prepared to date, the majority of these
chemiluminescent compounds is of no use as label for immunoassay, since they are too
unstable at room temperature. As an exception, adamantylideneadamantane 1,2-dioxetane
and its derivatives such as (1), hown in Figure 1, are extremely stable (the half-life of the
parent compound at 20°C is 16,000 years)6,7 and therefore (1) is suitable as a TCL label for
immunoassay. The chemiluminescence signal of this compound (1) is obtained by thermal
activation; the half-life of the label in our thermochemiluminescence detection apparatus5 is
about 25 s at 240°C.
The chemiluminescence efficiency of (1) is 5.10-5. This efficiency can be increased using
a fluorescent acceptor (3), which is covalently attached to the TCL-labeled protein (2),9 No
self quenching is observed upon coupling of more than one label (1) to a protein, since there
is no overlap between the weak UV absorption and the chemiluminescence spectrum of this
label. Hence, proteins labeled with (1) and (3) result in conjugates with a high
chemiluminescence efficiency (4.10-2). Such dually labeled proteins (antibodies, antigens, or
protein-protein conjugates thereof) can be competitive with previously known labels
(enzymes, isotopes, fluorescent labels, chemiluminogenic labels)10-13 and their antibody (or
antigen) conjugates.
II. RESULTS
A. hCG ENZYME IMMUNOASSAY
In order to compare the thermochemiluminescence immunoassay with an existing sen-
sitive immunoassay, we chose the hCG enzyme immunoassay (Organon Teknika). This
immunoassay is based on the well-known sandwich principle.14 The assay was performed
with two monoclonals specific for two different determinants of the hormone. The combi-
nation of these two monoclonals was chosen so that cross-reactivity with strongly related
hormones (LH, TSH, FSH) was prevented.15 In Figure 2A the result of the hCG enzyme
immunoassay, performed on polystyrene microtitration strips, is shown. The detection limit
was at 1 IU hCG per liter, the sensitivity was 0.007 absorbance units per IU hCG per liter
and the mean precision over the range measured was 4.7%,* The detection limit was
determined using the following formula:
t0.95 * SD
DL  =  Ao  +  ¾¾¾¾ (1)
Ön
* Sensitivity  =  tangent of the slope of the immunoassay curve (sign l/[antigen]); precision  =  reproducibility of
a measurement; detection limit  =  a limiting value which can be distinguished from the zero value.
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FIGURE 1. Compound (1) can be coupled to proteins in a simple one-step procedure. Upon heating, the product
decomposes quantitatively into two adamantanone fragments. During this process photons are released with an
efficiency of 5.10-5. After coupling of (1) to an antibody, the conjugate (2) can be applied in a thermochemilu-
minescence immunoassay. By way of (intramolecular) Förster type energy transfer to an appropriate fluorescent
acceptor, e.g., 2-(N-succinimidyloxycarbonylpropyl)-9, 10-diphenylanthracene (3),8 th  chemiluminescence effi-
ciency is greatly enhanced.
in which DL = detection limit, A0 = background value at doses zero, and t0.95 = value from a
student t distribution which indicates that a value larger than t0.95 will occur only with a
chance of 5% (the value of t0.95 is dependent on the number of measurements), SD =
standard deviation (sn-1), and n = number of measurements.
Because the signal of the stable 1,2-dioxetane label is detected at a high temperature
(240 to 250°C), the solid phase for this type of immunoassay must be heat resistant. A
suitable heat resistant solid phase for immunoassay is Kapton 500H, a polyimide. In order
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FIGURE 2. (A) hCG-enzyme immunoassay performed on polystyrene microtitration strips. The incubation of
antigen and labeled antibody was performed in one step (incubation period 30 min). (B) An identical assay
performed on Kapton 500H disks. (·) Each point represents the mean value of four measurements. (o) Co fficient of
variation of each series of measurements.
to compare the hCG enzyme immunoassay with TCL immunoassay, the hCG enzyme im-
munoassay was also performed on disks of Kapton 500H (Figure 2B). Clearly, the assay on
Kapton 500H is of equal quality under the chosen circumstances, which are optimal for the
titration plate (see experimental part). Hence, Kapton 500 H can be used as the solid-phase
material in a comparative study concerning the enzyme, and a TCL immunoassay for hCG.
B. THERMOCHEMILUMINESCENCE IMMUNOASSAY (TIA)
All thermochemiluminescence immunoassays reported in this chapter were performed on
Kapton 500H. In Figure 3, the chemical structure, the thermoluminescence characteristics of
this material (between 100 and 250 °C), and a typical TCL curve in time from an aliquot of a
solution of a 1,2-dioxetane labeled protein on this polymer are shown.
A TIA with monoclonal anti-hCG, labeled with ten residues (1) (specific activity 6.105
photon counts per microgram antibody, measured on Kapton 500H with the standard TCL
reader,5 fapp = 1.4*10
-3), was performed (Figure 4). Pretreated Kapton disks, which were
physically coated with monoclonal anti-hCG were used as the solid phase. The
circumstances of the immunoassay correspond with the hCG enzyme immunoassay on
Kapton 500H, except for the incubation volume (Figure 2).
It can be concluded that (i) the dynamic range of the immunoassay is large (over three
orders of magnitude), (ii) the sensitivity is »5 photon counts per International Units hCG per
liter, (iii) the detection limit is 10 IU hCG per liter (determined by formula 1), and (iv) the
mean precision over the total range measured is 15.5%. The measurements were perfor d
with an automated TCL reader.5 Table 1 shows the intra-assay precision of this
immunoassay, the influence of the conjugate concentration, and the influence of the incu-
bation time. It can be concluded that (i) no large differences between measurements on 2
separate days are observed, (ii) at a higher concentration of the conjugate (86.5 mg/ml ins ad
of 18.4 mg/ml), an increased background luminescence and an increased sensitivity (by factor
1.4) is observed, and (iii) after an incubation period of 1 h, the antibody-antigen binding
reaction is already in equilibrium.
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FIGURE 3. (A) Chemical structure of Kapton 500H. (B) Thermolumi-
nescence (background) of cleaned Kapton 500H at 100 to 250°C under an
atmosphere of nitrogen. (C) Curve in time of a typical TCL measurement
of a 1,2-dioxetane labeled protein (bovine serum albumin) on a Kapton
disk at 100 to 250°C.
In order to improve this TIA, the specific activity of the labeled antibody was increased
by covalently attaching high numbers of label residues per antibody molecule. The results of
such conjugates (labeled with respectively 20 and 26 residues of 1) in TIA are shown in
Table 2. An increase in sensitivity was observed especially for the antibody labeled with 26
residues (1). The detection limit was not lowered significantly and the precision was equal to
the above mentioned TIA.
The immunoreactivity of the three TCL conjugates, relative to that of the native antibody,
was determined using a competitive solid-phase sandwich immunoassay. Thus, the immune
reactivity of the antibody, labeled with 10,20, or 26 residues (1), was found to be 54%, 21 %,
and 11 %, respectively. A sample of urine of a pregnant woman, measured accordingly,
showed a signal indicating an hCG concentration of far above 2000 IU hCG per liter.
From these TIAs it can be concluded that:
1. A sensitive immunoassay can be performed using stable 1,2-dioxetanes as the sole
label, attached to an antibody; compared to the hCG enzyme immunoassay, however,
the TIAs still show a poorer precision and a detection limit.
2. The dynamic range of the TIAs is much larger than that of the corresponding enzyme
immunoassay.
FIGURE 4. hCG-TIA on antibody coated Kapton 500H disks. The conjugate was labeled with
10 residues (1). (·) Each point represents the mean of five measurements. (o) Precision CV).
TABLE 1
TCL Immunoassay: Intra-Assay Precision; Influence of
Incubation Time and Conjugate Concentration
TCL (in Photon counts; CV in %)a
hCG concentration (in IU/l)
0 200 2000 nb
Intra-assay precisionc
Day 1 598(17.9) 1,201(12.8) 7,283(12.8) 6
Day 2 483(32.5) 1,397(14.5) 6,630(17.1) 6
Incubation time
1 h 608 (5.1) 1,577 (7.6) 7,204 (8.1) 3
16 h 598(17.9) 1,201(12.8) 7,283(12.8) 6
Conjugate concentration
1-h incubation
18.4 mg/ml 608 (5.1) 1,577 (7.6) 7,204 (8.1) 3
86.5 mg/ml 1,140(23.9) 2,364(19.7) 11,886 (9.8) 4
16-h incubation
18.4 mg/ml 598(17.9) 1,201(12.8) 7,283(12.8) 6
86.5 mg/ml 793(21.8) 1,988 (9.9) 12,156(17.5) 7
a CV  =  coefficient of variation.
b Number of measurements.
c Concentration conjugate 18.4 mg/ml. Immunoassays shown were performed
on Kapton 500H (temperature 240°C, measuring time 2 min).
222 Luminescence Immunoassay and Molecular Applications
223
TABLE 2
Influence of the Number of Residues of Label (1), Covalently Coupled to
Monoclonal Anti-hCG, on TIA
Conjugate Number TCL (in photoncounts; CV in %)a Urine of a
conc. (in mg/ of (1) in hCG concentration (in IU/l) Pregnant
Entry ml) abb 0 200 2000 Womanc
1 29.4 20d 696(10.3) 1,359(21.1) 8,798 (2.0)
2 86.4 20 870(45.0) 1,995(25.9) 5,566(22.6)
3 29.4 26c 1,460 (4.9) 5,061 (7.3) 33,650 (8.8)
4 86.4 26 3,279(49.4) 6,258(40.9) 26,887(50.3) 76,897(25)
a TCL measurements (n  =  3) were performed at 240°C for 2 min. CV  =  coefficient of variation.
b Number of residues (1) covalently coupled to antibody.
c 12th week.
d Specific activity 1.3*106 counts/mg antibody (on Kapton 500H).
e Specific activity 1.7*106 counts/mg antibody (on Kapton 500H).
TABLE 3
Specific Activity of Monoclonal Anti-hCG Labeled with Different Numbers of
Residues of (1) and (3)
Specific activity
Molar ratio antibody: Number of (1) bound (in photon counts Light units (1) per an-
Entry (1):(3) during labeling to antibody *106/mg)a tibody moleculeb
1 1:25:0 10 0.6 10
2 1:50:0 20 1.29 20
3 1:100:0 26 1.77 27
4 1:25:89 10 6.0 91.5
5 1:50:89 20 10.8 165
6 1:100:89 26 18.7 285
7 1:200:500c n.d.d 50 762
8 1:180:89c n.d.d 10.1 154
a TCL measurements were performed on Kapton 500H. The antibody was dissolved in borate buffer (100 mM;
pH 8.5).
b TCL is expressed in units chemiluminescence of (1). The chemiluminescence of (1) is amplified by (3) and
hence the number of residues of (1) and 3) is substantially lower than the indicated CL units.
c Label (1) and (2) were covalently coupled to the antibody in a one step procedure.
d Not determined.
3. The use of antibody conjugates, containing more than ten residues of label (1), results
in an increased sensitivity, but does not improve TIA with respect to the detection
limit.
4. The presence of either urine or serum in a sample submitted to TIA does not dra-
matically quench the 1,2-dioxetane signal.
5. Labeling with (1) does not dramatically reduce immune reactivity of the antibody.
C. FLUORESCENT THERMOCHEMILUMINESCENCE IMMUNOASSAY (FTIA)
The specific activities of the TCL conjugates can be increased by concurrent labeling of
monoclonal anti-hCG with (1) and the highly fluorescent singlet energy transfer acceptor
(3). The specific activities of different conjugates labeled with varying numbers (1) and (3)
are shown in Table 3. The standard labeling reaction of this antibody with (1) resulted in a
labeling efficiency of 26 to 40% (determined by TCL measurement). Subsequent labeling






Conjugate concentration (m IU/l) (n = 3)
Entry (molar ratio antibody 1:3 during labeling) (in mg/ml) 0 200 2000
1 1:25:89 29.4 1,767 3,209 23,297
(35.6)a (39.3) (9.9)
2 1:25:89 86.4 4,198 5,392 32,547
(9.7) (12.1) (22.6)
3 1:50:89 29.4 2,712 7,462 65,234
(27.4) (1.1) (17.3)
4 1:50:89 86.4 6,031 13,707 96,667
(33.3) (12.0) (39.1)
5 1:100:89 29.4 26,090 31,527 314,238
(7.7) (15.7) (16.6)
6 1:100:89 86.4 67,071 62,380 287,310
(18.6) (74.1) (44.7)
7 1:200:500 7.5 7,228 15,415 72,476
(2.6) (12.3) (26.3)
8 1:200:500 20.0 14,994 26,053 84,197
(30.1) (6.6) (17.1)
9 1:180:89 3.0 576 2,891 17,249
(19.9) (26.6) (32.9)
10 1:180:89 6.0 908 4,121 25,830
(9.6) (16.4) (27.9)
11 1:180:89 1.5 588 4,599 14,701
(3.4) (15.5) (21.3)
a CV  =  coefficient of variation in percent.
of the conjugates with (3) (entries 4, 5, and 6) resulted in a TCL amplification of a factor
»10. A one pot labeling reaction of the antibody with (1) and (3) (entries 7 and 8) resulted in
conjugates with CL efficiencies up to 1 to 4% (the incorporated number of residues of (1)
and (3) in the product of entry 7 is estimated to be 50 and 15, respectively).
All conjugates were screened for their performance in a solid-phase sandwich immu-
noassay analogous to the above-mentioned TIA. In Table 4, the immunoassay (FTIA) results
for the quantification of three concentrations of hCG using these conjugates are shown. The
conjugate concentration was varied as well, in order to search for the optimal condition for
each conjugate.
In Figure 5, FTIAs are shown using different conjugates at optimal conjugate concen-
trations. The antibody, which was brought in reaction with 25 equivalents (1) and 89
equivalents (3) (Table 3, entry 4), was chromatographed over Sephadex® PD-10 (Pharmacia)
once before use, in order to remove traces of (3) still present after dialysis. This reduces
blank values of the immunoassay. Compound (3) is very hydrophobic and is poorly soluble
in aqueous buffer. Removal of noncovalently bound (3) fr m a crude conjugate solution was
rather difficult. Even the dialyzed and Sephadex PD-10 purified conjugate showed
noncovalently bound (3) in a SDS-polyacrylamide gel electrophoresis.
The immune reactivities of dually labeled proteins of entries 4, 5, and 6 (Table 2) were
36%, 20%, and 3% of that of the unlabeled antibody, respectively. Surprisingly, labeling of
antibody with large numbers of label (1) and (3) does not affect immune reactivity
dramatically. Even the conjugate “1:200:500” (entry 7, 8; Table 4) can be used in a TCL
immunoassay.
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FIGURE 5. FTIA using the conjugates of Table 3, entries 4 (A; n = 6), 6 (B,C; n = 3), and 8 (D; n = 6).
Conjugate concentration: A, 3 m/ml; B, 14 mg/ml; C, 7 mg/ml; and D, 3 mg/ml. The arrows in the graphs indicate
the detection limit (calculated according to formula (1)).
All measurements were performed with an automated TCL reader. A typical example of
the presentation of these data is shown in Figure 6. The TCL curves (intensity vs. time),
obtained from samples containing 0, 200, and 2000 IU hCG per liter, all have the same shape
because the thermal decomposition of the 1,2-dioxetane residues is a first order process. This
allows a standard heating program and a standard period of time for all measurements.
Application of antibodies, labeled with both (1) and (3), resulted in an increased blank
value in FTIA compared to the corresponding TIA. The hydrophobicity of (3) is l kely to
cause an increased tendency to aspecific binding of the conjugate to the solid phase.
However, since both the relevant signal and the blank value increased (more than was
expected from the increased specific activity of the antibody), the net result of the FTIA was
superior to that of the TIA. The major improvement was obtained in sensitivity of the assay.
Furthermore, a minor improvement of the detection limit was reached. Although counting
statistics play a diminished role in FTIA, a net improvement in precision was not observed.
It is surprising that very heavily labeled conjugates (entries 7 and 8; Table 3) still can be
used in a FTIA (entries 7 to 10; Table 4). However, such a heavily labeled antibody gives
rise to a further increase in the blank value of the immunoassay; a compromise must be
found between maximal specific activity and minimal background luminescence due to
aspecific binding.
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FIGURE 6. A typical example of the presentation of data of an hCG-TCL immunoassay. Wells no. 21,
31, and 41 show the immunoassay result for 2000, 200, and 0 IU/l hCG in human serum, respectively. At
the left side, the TCL curve in time is shown and at the right side, the maximum number of photon counts
per time interval (1.2 s) and the total number of photon counts of the TCL measurement (72 s) are printed.
At the upper side, a presentation is given of the wells, which will be measured by the automated TCL
reader (0 = not measured; 1 = measured by the automated TCL reader; well 1 at bottom right, well 60 at
upper left side).
D. QUENCHING PHENOMENA IN A THERMOCHEMILUMINESCENCE
IMMUNOASSAY
A remarkable observation in the TCL immunoassays shown was the relatively high
signal at high concentrations of hCG (> 200 IU hCG per liter) and the relatively low
luminescent signal at low concentrations of hCG (<200 IU hCG per liter). This fact (which is
not observed in the corresponding enzyme immunoassay) can be explained by a quenching
phenomenon playing an increasingly important role at lower levels of antibody conjugate
present on the Kapton 500H solid phase. In Figure 7 the TCL of Kapton 500H disks, coated
with bovine serum albumin labeled with (1) and washed with borate buffers of varying
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FIGURE 7. Influence of wash procedures using borate buffer of different
molarities on the TCL of Kapton 500H disks coated with BSA labeled with both
(1) and (3). Vertical axis: photon counts from Kapton 500H disks, coated with
TCL labeled BSA (each dot represents the mean value of six disks). Horizontal
axis: molarity of borate buffer used in the wash procedure after coating.
molarities, is shown. When coated disks were washed with distilled water, only a minor
fraction (2%) of the 1,2-dioxetane residues was detected by TCL measurement. Washing
with borate buffers of high molarities, however, resulted in the detection of all of the
expected TCL. (The background luminescence of the borate buffer was negligible at all
molarities). The increase of TCL in the presence of borate buffer can be explained by
complex formation of borate salts and 1,2-dioxetane residues at 240°C. This complexing
prevents the 1,2-dioxetane TCL from quenching by all kinds of compounds (e.g., metals)
present on the surface and partially embedded in the Kapton 500H material. Kapton 500 H
disks coated with bovine serum albumin labeled with 125I showed that about 400 to 800 ng
BSA/cm2 was coated on Kapton 500H. This corresponds nicely with the amount of TCL
found from the disks, coated with TCL labeled albumin and washed with the borate buffers
of optimal molarity (Figure 7).
For the above mentioned reason, the Kapton 500H disks were washed with 100 mM
borate buffer after the incubation of antigen and antibodies. Higher molarities of borate
buffer were not used, because of practical reasons (The pick up mechanism of the automated
TCL reader was contaminated upon use of borate buffers of high molarity).
We are tempted to believe that, especially at low concentrations of the antigen in a
thermochemiluminescent immunoassay, such quenching, despite the presence of 100 mM
borate buffer, occurs. Treatment of the Kapton disks in such a way that TCL quenching
impurities on the surface of this solid-phase material are removed, is a goal for the near
future.
III. DISCUSSION
Sensitive TCL immunoassays are possible. Until now, neither the hCG TIA nor the hCG
FTIA is competitive with a sensitive hCG enzyme immunoassay. Probably, this is caused by
a decrease of TCL by quenching of the stable 1,2-dioxetane luminescence by impurities,
present on the surface of Kapton 500H. It was proven that such quenching can be inhibited by
complexation of the 1,2-dioxetane with b- and g-cyclodextrin.9 Presently, work is done to
change the Kapton 500H surface to such an extent that luminescence quenching of a
monomolecular layer of 1,2-dioxetane labeled proteins is reduced substantially.
Another possibility to improve the TCL immunoassay is the development of a label,
containing a combination of a stable 1,2-dioxetane moiety and an efficiently fluorescent
singlet energy acceptor. Thus, an extremely high specific activity of a conjugate can be
obtained without the need of coupling many labels to an antibody. As a consequence, both
the affinity and the immune kinetics of the conjugate are expected to be preserved more
efficiently.
The advantages of using stable 1,2-dioxetanes in immunoassay are (i) the high specific
activity of antibodies labeled with both (1) and (3), (ii) the large range of antigen
concentration that can be measured by TCL immunoassay; the range of measurement of
stable 1,2-dioxetanes is only restricted by the apparatus used (our apparatus has a measuring
range of seven orders of magnitude), (iii) the inherently present signal (the signal is switched
on simply by raising the temperature, without the need of a waiting time or additional
chemicals), and (iv) the background luminescence in the immunoassay solely originates from
the 1,2-dioxetanes. Proteins show very low background luminescence upon heating under an
atmosphere of nitrogen.
A present disadvantage of the TCL technique is the need of a special heating apparatus.
Although we were able to design a device, capable of heating a sample (or a series of
samples) from room temperature up to 250°C within a few seconds, improvement is
obviously needed. The precision of the TCL assay being inferior by »5% t  that of the
enzyme immunoassay can be partly explained by the heating system allowing substantial
variation in the temperature program during TCL detection. Other possibilities to decompose
1,2-dioxetanes are laser excitation,16-18 room temperature catalytic luminescent
decomposition of stable 1,2-dioxetanes,19 and chemical and enzymatic triggering of suitably
substituted 1,2-dioxetanes.20-22 It is clear that the ultimate use of stable 1,2-dioxetanes as
labels (or enzyme substrates) for immunoassay has not yet been achieved. (See Chapter 17.)
IV. EXPERIMENTAL PART
A. MATERIALS
Bovine serum albumin (Sigma, Fraction V), Sephadex® PD-10 (Pharmacia), boric acid
(Merck), sodium tetraborate (Merck), and Tween® 20 (Sigma) were used without further
purification. Kapton 500H was purchased from Dupont in sheet format. Monoclonal anti-
hCG, hCG standards, and peroxidase labeled monoclonal anti-hCG were kindly provided by
Dr. T. C. J. Gribnau and Mr. T. van Sommeren (Organon Int. BV/Organon Teknika).
B. CLEANING OF KAPTON 500H DISKS
Sheets of Kapton 500H were cut in disks (f9 mm). These disks were refluxed in EtOH
during 4 h. The ethanol was replaced four times. Hereafter, the disks were refluxed during 1 h
in distilled water. The distilled water was replaced once. Refluxing in H2O longer than 1 h
resulted in swelling of the disks.
After refluxing and thoroughly washing the disks with excess cold distilled water, the
disks were transferred into a glass petri dish and heated for 2 h in an oven at 300°C.
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The background TCL of such cleaned disks was checked in the TCL reader. Optimally
cleaned Kapton 500H disks showed a background of less than 150 counts per minute.
C. ENZYME IMMUNOASSAY
1. Coating of Kapton 500H Disks with Monoclonal Anti-hCG
About 500 disks were put in an Erlenmeyer flask (200 ml) containing 70 ml of a solution
of 40 mg monoclonal anti-hCG per milliliter in a coating buffer containing 0.14 M NaCl,
1.5% (w/v) polyethylene glycol 6000, 6% saccharose, and 4.8 g NaH2PO4 per liter, pH 7.4
(Q).
Coating was performed at 4°C overnight, without shaking. Subsequently, the disks were
incubated during 2 h in 1% BSA (70 ml) in the above mentioned buffer (Q) at room
temperature. Hereafter, the disks were thoroughly washed with 200 ml buffer Q. Disks were
stored in buffer Q, containing 0.05% NaN3.
2. Coating of Microtitration Plates with Anti-hCG
Microtitration plates (Polystyrene, Organon Int.) were coated in the manner described
above. To each well, 135 ml of a solution of 40 mg antibody per milliliter buffer Q was
added. Subsequently, the plates were coated overnight, preincubated with 1% BSA in buffer
Q during 2 h, and thoroughly washed with buffer Q. The microtitration plates were dried
over silica, sealed in aluminum bags, and stored at 4°C.
3. hCG Enzyme Immunoassay on Kapton 500H
Kapton 500H disks, coated with monoclonal anti-hCG, were put in a home made
microtitration plate, consisting of a PVC holder containing 60 tube plugs (f12.5 mm). The
tube plugs were used as wells for the immunoassay. The disks were washed twice with 100
ml borate buffer (100 mM; pH 8.5). Subsequently, the disks were incubated with hCG
standards in human serum and peroxidase labeled anti-hCG (total volume 100 ml) on a
Sarstedt TPM-2 shaking machine during 30 min, and washed 3 times with the borate buffer.
Finally, 200 ml of a solution containing 3.3', 5.5'-tetramethyl benzidine and urea hydrogen
peroxide was added. The development of blue color was stopped with 200 ml 1 N H2SO4
after 30 min. The resulting yellowish color was measured in a twin reader at 450 nm by
putting 200 ml of the colored solution in a clean microtitration plate.
For the incubation of Kapton 500H disks during the immunoassay, 200 ml of solvent is
needed in order to have the surface of the Kapton 500H disks embedded properly.
Nevertheless, only 100 ml was used during the incubation of hCG and peroxidase labeled
antibody to allow optimal comparison between the different assay types. For practical rea-
sons, twice (200 ml) the standard volume for color and stop-reagent solution had to be taken.
Consequently, the signal found in Figure 2 for Kapton 500H must be multiplied by a factor
2 for a comparison with the hCG enzyme immunoassay on microtitration plate (Organon
Teknika). This concession leads to suboptimal results for the Kapton 500H enzyme
immunoassay.
4. hCG Enzyme Immunoassay on Microtitration Plates
The immunoassay was performed as described above except for the volume of colorand
stop-reagents (100 ml).
D. LABELING OF ANTI-hCG WITH 1,2-DIOXETANE LABEL (1)
Into 1 ml of a solution of 3.1 mg monoclonal anti-hCG per milliliter in 0.9% NaCl was
pipetted 1 ml borate buffer (100 mM, pH 8.3) and 200 ml of a solution of 1.25 mg (1) per
milliliter in 1,4-dioxane (molar ratio antibody: (1) = 1:25). The solution remained clear. The
reaction was performed at room temperature during 2 h. The product was purified by
dialysis against borate buffer (100 mM, pH 8.3; three times 1:1). The labeled antibody was
stored in borate buffer (100 mM, pH 8.3; 0.05% NaN3) at 4°C. The heavily labeled
conjugates (Table 3, entries 2, 3) were prepared in the same way, except that the volume of
the freshly prepared solution of label added was changed to 100 ml 5 mg (1) per milliliter
and 200 ml 5 mg (1) per milliliter, respectively.
E. DUAL LABELING OF ANTI-hCG
To 1 ml of a 1.47 mg/ml solution of 1,2-dioxetane labeled anti-hCG (entries 1, 2, and 3;
Table 3) in borate buffer (100 mM, pH 8.5) was added 50 ml of a solution of 8.7 mg (3) per
milliliter in 1,4-dioxane. The reaction mixtures immediately turned turbid upon the addition
of (3). The reactions were allowed to remain for 5 h at room temperature, with gentle stirring
(magnetic bar). Thereafter, insoluble material was removed by centrifugation (Eppendorf
centrifuge). The supernatant was dialyzed against several changes of borate buffer (100 mM,
pH 8.5).
The conjugate “1:25:89” (entry 4; Table 3) was further purified on a Sephadex® PD-10
column (Pharmacia) with borate buffer (100 mM, pH 8.5) as the eluent.
Conjugates of entries 7 and 8 (Table 3) were prepared by adding (1) and (3) simulta-
neously (antibody concentration 1 mg/ml during the labeling reaction). The reaction con-
ditions were identical to those of the above-mentioned procedure. In both cases, the reaction
turned turbid.
F. DETERMINATION OF IMMUNE REACTIVITY OF LABELED ANTIBODY
Wells of a microtitration plate, coated with anti-hCG, were incubated with 200 IU hCG
per liter, 0.1 mg anti-hCG labeled with peroxidase, and different amounts of unlabeled
monoclonal antibody during 30 min. The microtitration plate was washed three times with
distilled water (200 ml), and the peroxidase activity was determined as described above. The
immune reactivity of labeled antibodies was determined by means of a reference curve of the
unlabeled antibody. The labeling procedure in which 5% 1,4-dioxane was used did not lead
to a diminished immune reactivity.
G. THERMOCHEMILUMINESCENCE IMMUNOASSAY
Kapton 500H disks were coated with anti-hCG as described above. The disks were
washed once with borate buffer (100 mM, pH 8.5) in a PVC petri dish (about 10 ml borate
buffer per 100 disks). Thereafter, the disks were transferred to plug stops (12.5 mm; Tho-
vadec) which were placed in home made microtitration holders. Each plug contained 200 ml
borate buffer (100 mM, pH 8.5).
A vial from a frozen stock solution of hCG (10,000 IU/l) in 0.9% NaCl was diluted in a
solution containing bovine serum in such a way that all standards contained 80% bovine
serum and 0.9% NaCl. Finally, the conjugate was diluted in bovine serum. The incubation
volume was 160 ml. The disks were shaken during incubation. After the incubation, the disks
were washed three times with 300 ml borate buffer (100 mM, pH 8.3). Then, the disks were
stored in 200 ml borate buffer until the TCL measurement was performed.
H. FTIA FOR hCG
This immunoassay was identical to that described for TIA, unless stated otherwise in the
text. All immunoassays performed with dually labeled conjugates were done at room
temperature during 1 h on a shaking plateau (Sarstedt TPM-2).
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